Anthropic Acquires Biotech AI Startup Coefficient Bio for $400 Million

Apr 3, 2026

Anthropic has acquired Coefficient Bio, an eight-month-old biotech AI startup, for just over $400 million in an all-stock deal that brings fewer than 10 former Genentech computational biology researchers into Anthropic's healthcare division. The acquisition, first reported by The Information on Thursday, represents minimal dilution at 0.1 per cent against Anthropic's $380 billion post-money valuation from its February Series G round. Coefficient Bio, co-founded by Samuel Stanton and Nathan C. Frey from Genentech's Prescient Design unit, never left stealth mode and had no publicly known product or revenue, yet delivered investor Dimension a 38,513 per cent internal rate of return. The deal marks Anthropic's aggressive push into AI-driven drug discovery following its October 2025 launch of Claude for Life Sciences, competing directly with Google DeepMind's Isomorphic Labs and OpenAI's pharmaceutical partnerships as the sector attracts billions in venture capital.

Anthropic's $400 Million Acquisition of Coefficient Bio

▪Anthropic acquired Coefficient Bio in an all-stock deal worth just over $400 million.
▪The Anthropic acquisition of Coefficient Bio represents roughly 0.1 per cent dilution against Anthropic's $380 billion post-money valuation.
▪The Anthropic acquisition of Coefficient Bio brings a team of fewer than 10 people into Anthropic's healthcare and life sciences division.
▪Coefficient Bio was founded barely eight months ago before being acquired by Anthropic.
▪Anthropic raised $30 billion in a Series G round in February at a $380 billion post-money valuation.

Coefficient Bio's Founding Team and Capabilities

▪Nathan C. Frey's publication record spans more than 20 papers in journals including Science Advances and Nature Machine Intelligence.
▪Nathan C. Frey won an ICLR Outstanding Paper Award in 2024 for work on generative modelling for drug candidate discovery.
▪Dimension was founded in 2023 by former Lux Capital and Obvious Ventures partners Adam Goulburn, Zavain Dar, and Nan Li.

Strategic Push into Healthcare and Life Sciences AI

▪Anthropic launched Claude for Life Sciences in October 2025.
▪Anthropic's run-rate revenue has reached $14 billion.
▪Eric Kauderer-Abrams was hired by Anthropic in 2025 with an explicit mandate to make Claude the dominant AI model in biology.
▪Dimension is reportedly raising a $700 million third fund to invest in AI-biology companies.
▪Breakout Ventures closed a $114 million fund in March explicitly targeting early-stage biotechs that treat AI and biology as inseparable.
▪Anthropic's customer base spending over $100,000 a year on Claude has grown sevenfold.

Competitive Landscape in AI-Driven Drug Discovery

▪Nvidia announced a five-year, $1 billion partnership with Eli Lilly in January to build an AI co-innovation lab for accelerated drug discovery.

Perspective of Dimension

▪Dimension's strategy of backing AI-biology companies at the intersection of technology and life sciences is attracting capital for a reported $700 million third fund.

Perspective of Anthropic

▪Anthropic's $400 million acquisition of Coefficient Bio represents minimal dilution at 0.1 per cent against its $380 billion valuation, making the talent acquisition strategically affordable.
▪Anthropic sees drug discovery and biological research as a critical expansion area following the October 2025 launch of Claude for Life Sciences.

Perspective of AI-biology venture investors

▪Breakout Ventures' $114 million fund targeting early-stage biotechs treating AI and biology as inseparable reflects investor conviction in AI-driven drug discovery.

Perspective of Competing AI companies in drug discovery

▪Nvidia's five-year, $1 billion partnership with Eli Lilly to build an AI co-innovation lab demonstrates that major tech companies are competing for pharmaceutical industry partnerships.